Cost-effectiveness of the MitraClip device in secondary mitral regurgitation: comment upon the article by Estler et al [0.03%]
关于Estler等人的文章中有关MitraClip装置在继发性二尖瓣反流中的成本效益的评论
Martin Connock,Xavier Armoiry
Martin Connock
Completing the time trade-off with respondents who are older, in poorer health or with an immigrant background in an EQ-5D-5L valuation study [0.03%]
基于EQ-5D-5L估值得出的时间交易研究中老年、健康欠佳或有移民背景的受试者的研究
Tonya Moen Hansen,Knut Stavem,Kim Rand
Tonya Moen Hansen
Objectives: To determine the effects of age, immigrant background, and poor self-reported health in a general population sample on the probability of non-completion or slow completion of the time trade-off (TTO). ...
"The reputation premium": does hospital ranking improvement lead to a higher healthcare spending? [0.03%]
“声望溢价”效应：医院排名的提升会增加医疗开支吗？
Jinyang Chen,Chaoqun Wang
Jinyang Chen
Global health systems have often disclosed hospital quality and performance information via hospital ranking or rating programs over the last 20 years. This study aims to examine the relationship between hospital ranking and healthcare spen...
Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France [0.03%]
一种非瓣膜性房颤口服抗凝药的对比研究：从真实世界的角度比较不同药物的相关费用和整体费用（法国）
Manon Belhassen,Olivier Hanon,Philippe Gabriel Steg et al.
Manon Belhassen et al.
Objectives: Compare costs associated with all-cause healthcare resource use (HCRU), stroke/systemic thromboembolism (STE) and major bleedings (MB) between patients with non-valvular atrial fibrillation (NVAF) initiating a...
Trends and drivers of pharmaceutical expenditures from systemic anti-cancer therapy [0.03%]
抗癌药物支出及其驱动因素的趋势分析
Lars Børty,Rasmus F Brøndum,Heidi S Christensen et al.
Lars Børty et al.
Expenditures on medicine for systemic anti-cancer therapy (SACT) have seen large increases in recent years. The characterization of patients with high SACT costs is crucial to identify cost-driving factors, but little is known about the dis...
Dividend policy issues in the European pharmaceutical industry: new empirical evidence [0.03%]
欧洲制药行业的分红政策问题：新的实证证据
Tobias Basse,Christoph Schwarzbach,J-Matthias Graf von der Schulenburg
Tobias Basse
This paper examines dividend policy issues in the European pharmaceutical industry. This sector is of particular interest because of the high research and development expenditures and the associated risks characterizing the business models ...
Assessing Taiwan's pay-for-performance program for diabetes care: a cost-benefit net value approach [0.03%]
台湾糖尿病护理的绩效激励方案的成本效益评估研究
Jui-Fen Rachel Lu,Ying Isabel Chen,Karen Eggleston et al.
Jui-Fen Rachel Lu et al.
Pay-for-Performance (P4P) to better manage chronic conditions has yielded mixed results. A better understanding of the cost and benefit of P4P is needed to improve program assessment. To this end, we assessed the effect of a P4P program usi...
Were we happy and we didn't know it? A subjective dynamic and financial assessment pre-, during and post-COVID-19 [0.03%]
疫情前后我们快乐却浑然不觉吗？基于主观动态和金融评估的分析
Gabriela-Mihaela Mureșan,Viorela-Ligia Văidean,Codruța Mare et al.
Gabriela-Mihaela Mureșan et al.
The COVID-19 pandemic has brought many changes into people's lives. Fear, job insecurity, changes in their financial stability, concerns about their future lives have changed the entire lives of people and have affected the cognitive well-b...
The 'welcomed lockdown' hypothesis? Mental wellbeing and mobility restrictions [0.03%]
“受到欢迎的封锁”假说？心理健康与行动限制措施的关系
Joan Costa-Font,Martin Knapp,Cristina Vilaplana-Prieto
Joan Costa-Font
The COVID-19 pandemic and its mobility restrictions have been an external shock, influencing mental wellbeing. However, does risk exposure to COVID-19 affect the mental wellbeing effect of lockdowns? This paper examines the 'welcomed lockdo...
Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic [0.03%]
低发病率和低病死率条件下新冠疫苗的成本效果评估——以新冠疫情初期的泰国为例
Yi Wang,Nantasit Luangasanatip,Wirichada Pan-Ngum et al.
Yi Wang et al.
Objective: This study aimed to assess the cost-effectiveness of COVID-19 vaccines, preferred COVID-19 vaccine profiles, and the preferred vaccination strategies in Thailand. ...